Basel, Switzerland – January 2026 – Quant Biomarkers AG has secured approximately CHF 1 million in non-dilutive grant funding from Innosuisse to support the development and clinical validation of a biomarker test for earlier detection, progression assessment, and treatment monitoring of chronic kidney disease (CKD). The Innovation project supported by Innosuisse is advancing cutting-edge translational diagnostics through a strategic collaboration with top Swiss institutions, including Lausanne University Hospital (CHUV) and the University of Zurich (UZH). This partnership strengthens Switzerland’s leadership in life-science innovation and underscores our commitment to delivering transformative solutions with global impact.
Chronic kidney disease affects over 850 million people worldwide and is closely linked to prevalent cardio-metabolic conditions yet remains widely underdiagnosed as current standards detect disease only after significant loss of renal function. Quant Biomarkers’ program addresses this gap by enabling earlier biological detection of renal injury and clinically actionable monitoring of disease progression and therapy response. The technology is exclusively licensed from x-kidney diagnostics GmbH, a portfolio program of Xlife Sciences AG.
The Innosuisse funding reinforces Quant Biomarkers’ strategy to move beyond single-organ diagnostics toward an integrated systems-biology approach within the cardio-kidney-metabolic disease continuum, reflecting the bidirectional interplay between cardiovascular, renal, and metabolic disorders.
This Innosuisse grant validates our strategy to develop clinically actionable biomarkers for earlier diagnosis and improved treatment monitoring across cardio-kidney-metabolic disease,” said Dr. Sanja Baumann-Tomovska, Co-Founder and CEO of Quant Biomarkers AG. “RenoRisk turns kidney disease from a late-stage diagnosis into an early, actionable signal for clinicians, patients, and drug developers.’’
Prof. Dr. Menno Pruijm, Nephrologist, researcher and head of dialysis, CHUV, commented: “Over the past decade, many new medicines have been developed that can protect the kidneys early in the disease process. However, diagnostic tests have not kept pace with these advances. This project has the potential to close this gap by enabling earlier detection of kidney damage, when treatment is most effective.”
Prof. Dr. Carsten Wagner, 2025 European Renal Association Research Award winner and Group leader at the Zurich Kidney Center of UZH, commented: “The cooperation between innovative Industry partners and academic research expertise is important to develop novel approaches for better diagnosis and treatment of chronic kidney disease which remains a major disease problem.”
Alexander Zink, CSO of Xlife Sciences AG,
“The Innosuisse Innovation project award underscores the scientific robustness of the x-kidney platform and highlights the importance of early detection in transforming outcomes in chronic kidney disease’’.
About Quant Biomarkers AG
Quant Biomarkers AG is a Basel-based Swiss biomarker company developing clinically actionable biomarker solutions across the cardio-kidney-metabolic (CKM) disease spectrum, enabling earlier diagnosis, treatment monitoring, and disease progression assessment. The company collaborates with leading academic and clinical partners, including Lausanne University Hospital (CHUV) and the University of Zurich (UZH), to translate biomarker science into clinical practice.
About Innosuisse
Innosuisse is the Swiss Innovation Agency, promoting science-based innovation by supporting collaborative projects between companies, start-ups, and research institutions.
www.innosuisse.ch